These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7219643)

  • 1. Suppression of secondary hyperparathyroidism by propranolol in renal failure patients.
    Besarab A; Caro JF; Ihle BU; Burke JF; Glennon JA; Fischer JA
    Nephron; 1981; 27(3):127-33. PubMed ID: 7219643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 4. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy.
    O'Riordan JL; Page J; Kerr DN; Walls J; Moorhead J; Crockett RE; Franz H; Ritz E
    Q J Med; 1970 Jul; 39(155):359-76. PubMed ID: 5478506
    [No Abstract]   [Full Text] [Related]  

  • 8. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.
    Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K
    Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on the disturbances in calcium and bone disease: renal osteodystrophy in patients with chronic renal failure].
    Yoshidome E
    Igaku Kenkyu; 1987 May; 57(2):83-104. PubMed ID: 3673482
    [No Abstract]   [Full Text] [Related]  

  • 11. Secondary hyperparathyroidism in chronic renal failure.
    Wills MR; Savory J
    Ann Clin Lab Sci; 1981; 11(3):252-61. PubMed ID: 6264838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of strontium on bone metabolism in hemodialysis patients].
    Gerstenfeld S; Hinojosa L; Serrano Arias M; Menéndez Rodríguez P; Fernández Martín JL; Marchante JM; García Alonso JI; Sanz-Medel A; Cannata Andía JB
    Nefrologia; 2003; 23 Suppl 2():52-6. PubMed ID: 12778855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 15. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
    Rahamimov R; Silver J
    Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can a dietitian help prevent renal bone disease in the hemodialysis patient?
    Harum P
    Nephrol News Issues; 1990 Sep; 4(9):35, 37, 42. PubMed ID: 2402318
    [No Abstract]   [Full Text] [Related]  

  • 17. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 18. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.